SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-013896
Filing Date
2024-04-01
Accepted
2024-04-01 09:20:03
Documents
13
Period of Report
2024-04-01
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20240401.htm   iXBRL 8-K 26896
  Complete submission text file 0001628280-24-013896.txt   155666

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20240401.xsd EX-101.SCH 1904
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20240401_lab.xml EX-101.LAB 23449
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20240401_pre.xml EX-101.PRE 13583
16 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20240401_htm.xml XML 2824
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 24805929
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)